Ironwood, Allergan settle suit with Teva over IBS-C generic — 3 insights

Ironwood Pharmaceuticals and Allergan reached a settlement with Teva over Teva's abbreviated new drug application for a generic version of Linzess, a drug for irritable bowel syndrome with constipation.

What you should know:

1. Teva sought approval to market a generic version of Linzess, also known as linaclotide, before Ironwood and Allergan's patents expired.

2. Ironwood and Allergan granted Teva permission to market a 145 mcg and a 290 mcg generic version of Linzess in the U.S. effective March 31, 2029. However, Teva will not be allowed to market a 72 mcg version of Linzess.

3. The lawsuit between the companies will be dismissed if the settlement is approved by the Federal Trade Commission and Department of Justice.

More articles on gastroenterology:
Cardinal surgical gown quality issues cause surgery centers to reschedule procedures
California ASC partners with ORHub
Medline acquires device distributor in Canada

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months